Latest Bare-metal stent Stories
Trial shows that use of bivalirudin alone improves survival in heart-attack patients compared to heparin and a glycoprotein IIb/IIIa inhibitor; drug-eluting stents are also shown to be more effective than bare-metal stents, with equivalent safety.
MOUNTAIN VIEW, Calif., May 17, 2011 /PRNewswire/ -- AccessClosure, Inc., the market segment leader in extravascular closure devices, announced today an exclusive agreement with Biosensors International for the distribution of the Mynx(TM) Vascular Closure Device throughout the United Kingdom, Switzerland and France.
DURHAM, N.C., May 11, 2011 /PRNewswire/ -- Micell Technologies, Inc.
NATICK, Mass., April 25, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced U.S.
NATICK, Mass., April 5, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the start of patient enrollment in the SuperNOVA clinical trial, an international, prospective, single-arm, non-randomized trial evaluating the safety and effectiveness of the INNOVA(TM) Self-Expanding Bare-Metal Stent System in patients with stenosis of the superficial femoral artery (SFA) or proximal popliteal artery (PPA).
NATICK, Mass., March 29, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced its clinical trial news and events schedule at the 60th Annual Scientific Session of the American College of Cardiology/i2 Summit, April 2-5, 2011 in New Orleans. "Twelve-month results from the PLATINUM Workhorse clinical trial will provide important data on our next-generation PROMUS Element(TM) Everolimus-Eluting Platinum Chromium (PtCr) Stent as compared to our market-leading PROMUSÂ®...
NATICK, Mass., March 7, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its OMEGA(TM) Platinum Chromium Bare-Metal Coronary Stent System, the Company's third-generation coronary stenting technology.
DURHAM, N.C., Feb. 17, 2011 /PRNewswire/ -- Micell Technologies,(TM) Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial.
NATICK, Mass., Jan. 24, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY(TM) Coronary Stent.
HONG KONG, Dec.
- Sleep; the state or condition of being asleep.
- The state or condition of numbness of a part due to pressure on a nerve: as, the obdormition of a limb.